Choose Your Country or Region

Interleukins

Isoform-selective Products

IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 IL-3 IL-18

Interleukins Products

All (160)
Interleukins Inhibitors (60)
Interleukins Antibodies (85)
Interleukins Activators (5)
Interleukins Antagonists (3)
Interleukins Agonist (1)
Interleukins Modulators (4)
New Interleukins Products

Catalog No.	Product Name	Information	Product Use Citations
S7455	Resatorvid (TAK-242)	Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy.	Carbohydr Polym, 2025, 350:122980 J Neuroinflammation, 2025, 22(1):38 Phytomedicine, 2025, 142:156645
S1189	Aprepitant	Aprepitant is a potent and selective neurokinin-1 receptor antagonist with IC50 of 0.1 nM. Aprepitant reduces levels of pro-inflammatory cytokines including G-CSF, IL-6, IL-8 and TNFα. Aprepitant inhibits HIV infection of human macrophages.	Br J Cancer, 2024, 10.1038/s41416-024-02608-8 Inflammation, 2023, 46(1):256-269 Nat Commun, 2022, 13(1):4995
S1709	Estradiol	Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.	Nat Commun, 2025, 16(1):758 Cells, 2025, 14(10)703 iScience, 2024, 27(3):109125
S8966	T-5224	T-5224 is a selective inhibitor of transcription factor c-Fos/activator protein (AP)-1 with anti-inflammatory effects. T-5224 specifically inhibits the DNA binding activity of c-Fos/c-Jun and the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.	MedComm (2020), 2025, 6(4):e70154 iScience, 2025, 28(4):112176 J Immunol Res, 2025, 2025:4821639
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Int J Nanomedicine, 2024, 19:3589-3605 Front Immunol, 2024, 15:1331480 J Inflamm Res, 2024, 17:9757-9771
S6414	Apilimod	Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.	J Cell Biol, 2025, 224(6)e202408158 Cells, 2024, 13(11)953 bioRxiv, 2024, 2024.02.28.582543
S7259	FLLL32	FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.	Cancer Commun -Lond), 2023, 43(10):1117-1142 Microbiol Res, 2023, 276:127480 Research Square, 2023, Version 1
S8301	Ossirene (AS101)	Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme.	Mol Neurodegener, 2025, 20(1):5 Cell Biosci, 2025, 15(1):18 Stem Cell Rev Rep, 2025, none
S4267	Diacerein	Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.	MedComm (2020), 2024, 5(8):e668 Oral Dis, 2022, 10.1111/odi.14294 Free Radic Biol Med, 2021, 165:171-183
S1733	Methylprednisolone	Methylprednisolone is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis.	Food Chem Toxicol, 2024, 188:114665 Drug Test Anal, 2020, 10.1002/dta.2917 Nat Med, 2017, 23(4):424-428
S9727	Ac-YVAD-cmk	Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective IL-1β converting enzyme (ICE) inhibitor with neuroprotective and anti-inflammatory effects, effectively suppresses the expression of IL-1β and IL-18.	Cell Commun Signal, 2024, 22(1):368 J Transl Med, 2024, 22(1):1139 Int J Mol Sci, 2024, 25(4)2185
A2025	Secukinumab (anti-IL-17A)	Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.	American Scientific Publishers, 2024, 174-182(9) Signal Transduct Target Ther, 2022, 7(1):80 Biochem Pharmacol, 2021, 192:114728
S8261	GSK583	GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. GSK583 also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures.	J Invest Dermatol, 2025, S0022-202X(25)00494-4 Cancer Res, 2020, canres.530.2020 J Neuroinflammation, 2020, 17(1):364
S0785	Apilimod mesylate	Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.	bioRxiv, 2024, 2024.02.28.582543 Stem Cell Reports, 2022, 17(2):397-412 Hum Mol Genet, 2021, 29(22):3589-3605
S0787	3-Deazaadenosine hydrochloride	3-Deazaadenosine HCl (3-DZA, c3Ado) is a potent inhibitor of S-adenosylhomocysteine hydrolase with Ki of 3.9 µM. 3-Deazaadenosine HCl inhibits bacterial lipopolysaccharide-induced transcription of TNF-α and IL-1β. 3-Deazaadenosine HCl inhibits the transcriptional activity of NF-κB, prevents FCS-induced Ras carboxyl methylation and reduces FCS-induced ERK1/2 and Akt phosphorylation. 3-Deazaadenosine HCl has anti-inflammatory, anti-proliferative and anti-HIV activities.	J Exp Clin Cancer Res, 2022, 41(1):36 Free Radic Biol Med, 2021, 168:25-43
S9668	PKR-IN-C16	PKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.	Exp Mol Med, 2024, 56(2):408-421. EMBO J, 2024, 43(5):780-805. Respir Res, 2024, 25(1):201
S8879	Deucravacitinib (BMS-986165)	Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.	Res Sq, 2025, rs.3.rs-6079043 Nat Commun, 2024, 15(1):1718 Nat Commun, 2024, 15(1):1337
S2979	CU-T12-9	CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.	Nat Commun, 2025, 16(1):2743 Biomedicine & Pharmacotherapy, 2023, 114638 Biomed Pharmacother, 2023, 162:114638
S2015	Suplatast Tosylate	Suplatast Tosylate (IPD-1151T, Suplatast Tosilate) is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.	J Transl Med, 2022, 20(1):615
S6281	Sodium Thiocyanate	Sodium Thiocyanate (NaSCN, Sodium rhodanide, Sodium sulfocyanate, Sodium rhodanate), one of the main sources of the thiocyanate anion, is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals. Sodium thiocyanate (NaSCN) reduces IL-6, whereas increases IL-10 levels. Sodium thiocyanate also reduces ROS.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S0826	A-740003	A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. A-740003 potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells.	Am J Cancer Res, 2024, 14(2):585-600 Cell Rep, 2023, 42(7):112696
S6898	RCM-1	RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin.	Parasit Vectors, 2025, 18(1):100 J Mol Histol, 2024, 55(6):1259-1270 Front Immunol, 2022, 13:863034
S0771	BRD6989	BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA).	Infect Drug Resist, 2021, 14:3135-3143
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S5972	Hydrocortisone hemisuccinate	Hydrocortisone hemisuccinate (A-hydrocort, Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid with anti-inflammatory properties, is an inhibitor of proinflammatory cytokine with IC50 of 6.7 μM and 21.4 μM for Interleukin-6 (IL-6) and IL-3, respectively.	J Transl Med, 2023, 21(1):50
S9052	Auraptene	Auraptene (7-geranyloxycoumarin) is a natural coumarin derived from citrus plants and possesses valuable pharmacological properties, including anticarcinogenic, anti-inflammatory, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene inhibits matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8 and chemokine (C-C motif) ligand-5(CCL5).	Neuropharmacology, 2025, 269:110352 Plant Physiology, 2012, 81–94
S9374	2',5'-Dihydroxyacetophenone	2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.	Pathol Oncol Res, 2019, 25(1):301-309
S6620	Danirixin (GSK1325756)	Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 (IL-8) binding = 12.5 nM), selective, and reversible CXCR2 antagonist.	Redox Biol, 2024, 76:103323 Theranostics, 2019, 9(18):5332-5346
A2120	Anti-mouse IL-17A-InVivo	Anti-mouse IL-17A-InVivo monoclonal antibody (Clone:17F3) reacts with mouse IL-17A which is a 15-20 kDa cytokine expressed by Th17 cells, γδ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. Anti-mouse IL-17A-InVivo has been shown to neutralize IL-17A in vivo.	Autoimmunity, 2025, 58(1):2515825 World J Gastrointest Oncol, 2025, 17(1):97831 Int Immunopharmacol, 2024,
S0437	SAR-20347	SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling.	Cancer Discov, 2023, 13(2):410-431 Cancer Discov, 2023, 13(2):410-431
S3745	Balsalazide disodium	Balsalazide Disodium is the disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide Disodium suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.	Front Microbiol, 2020, 10:2936
S9502	Madecassic acid	Madecassic acid (Brahmic acid), a natural triterpene first isolated from C. asiatica, has diverse anti-inflammatory and anti-diabetic effects, blocking NF-κB activation in macrophages and causing by iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 inhibition.	Drug Des Devel Ther, 2022, 16:3793-3804
S0472	EC330	EC330 is a steroidal inhibitor of leukemia inhibitory factor (LIF, an interleukin 6 class cytokine). EC330 inhibits the LIF/LIF-R signaling and blocks the promoting effects of LIF on growth and migration of cancer cells.	NPJ Precis Oncol, 2024, 8(1):246 Br J Cancer, 2021, 10.1038/s41416-021-01631-3
F2146^New	IL-18 Rabbit mAb	IL18,IL-18
S1833	Butoconazole nitrate	Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively).
S3312	Diethyl phosphate	Diethyl phosphate (DEP, DPF, Diethyl phosphoric acid, diethyl hydrogen phosphate), a non-specific metabolite of organophosphorus pesticides in the gut environment, significantly enriches opportunistic pathogens leading to a decrease in interleukin-6 (IL-6).
S5764	YM 90709	YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).
S4842	Balsalazide	Balsalazide (Colazal, Giazo), an aminosalicylate and oral prodrug, is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
A2375	Rolinsatamab (Anti-PRLR / Prolactin Receptor)	Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD.
A2822	Depemokimab (Anti-IL-5)	Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD.
P1252^New	JNJ-77242113(Icotrokinra)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
A2142	Anti-mouse/rat IL-1β-InVivo	Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes.	Signal Transduct Target Ther, 2025, 10(1):161
S3590	Triolein	Triolein is an inhibitor of metalloproteinase-1 (MMP-1) and reduces both the expression of IL-6 and ROS generation in irradiated keratinocytes.
E3067	Trionycis Carapax Extract	Trionycis Carapax Extract is obtained from Carapax Trionycis, of which Carapax Trionycis extracts with molecular weight less than 6 KD (CT6) down-regulates TNF-α, IL-1β and IL-6 expression in TGF-β1-treated HSC-T6, indicating the potential therapeutic effect of these extracts against liver fibrosis.
E0314	JTE-607 Dihydrochloride	JTE-607 Dihydrochloride is a prodrug compound that is converted to an active form by ester hydrolysis. JTE-607 is a multiple cytokine production inhibitor that targets CPSF3 and inhibits pre-mRNA processing. JTE-607 inhibits tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50 values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively.
A2842	Ebdarokimab (Anti-IL-12b)	Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW : 145.6 KD.
A2153	Anti-mouse IL-2 (S4B6-1)-InVivo	Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation.
A2845	Elsilimomab (Anti-IL-6 / IFNb2)	Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD.
A2157	Anti-mouse IL-6R-InVivo	Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily.
S3969	Veratric acid	Veratric acid (3,4-Dimethoxybenzoic acid), a simple benzoic acid derived from plants and fruits, has anti-oxidant, anti-inflammation, and blood pressure-lowering effects. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation.
S9236	α-Cyperone	α-Cyperone (alpha-cyperone), a major active compound of Cyperus rotundus, exhibits biological activities, such as antivirulence, antigenotoxic, and antibacterial activities. α-Cyperone (alpha-cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1.
E3568	Natural indigo Extract	Natural Indigo Extract is extracted from Polygonum tinctorium, which suppress sodium dextran sulfate-induced colitis through interleukin-10-related pathway.
A2046	Risankizumab (anti-IL-23)	Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.
A2856	Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)	Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD.
S0752	AUDA	AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. AUDA has anti-inflammatory activity that reduces the protein expression of MMP-9, IL-1β, TNF-α and TGF-β. AUDA downregulates Smad3 and p38 signaling pathways.
A2861	Anti-CTLA-8 / IL-17a (CAT-2200)	Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72.
A2862	Ixekizumab (Anti-CTLA-8 / IL-17a)	Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD.
A2863	Netakimab (Anti-CTLA-8 / IL-17a)	Netakimab (Anti-CTLA-8 / IL-17a) is a humanized monoclonal antibody against interleukin-17 (IL-17) with the potential to treat moderate to severe plaque psoriasis. MW: 145.74 KD.
A2024	Ustekinumab (anti-IL-12/IL-23)	Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.
A2864	Perakizumab (Anti-CTLA-8 / IL-17a)	Perakizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG1κ monoclonal antibody against interleukin-17A (IL-17A). MW: 145.8 KD.
A2134	Anti-mouse IL-18-InVivo	Anti-mouse IL-18-InVivo (Clone:YIGIF74-1G7) monoclonal antibody reacts with mouse IL-18. IL-18 an 18 kDa pro-inflammatory cytokine is expressed by activated macrophages, keratinocytes, Kupffer cells, intestinal epithelial cells, and osteoblasts.
A2609	Clazakizumab (Anti-IL-6 / IFNb2)	Clazakizumab (Anti-IL-6 / IFNb2) is a monoclonal antibody targeting the IL-6 (interleukin-6). It inhibitsg the cytokine response to SARS-CoV-2 in COVID-19 and can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. MW :145.24 KD.
A2423	Enokizumab (Anti-IL-9)	Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD.
A2610	Vobarilizumab (Anti-IL-6Ra / CD126)	Vobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD.
A2866	Vunakizumab (Anti-CTLA-8 / IL-17a)	Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.
A2428	Mepolizumab (Anti-IL-5)	Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD.
A2430	Pascolizumab (Anti-IL-4)	Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD.
A2432	Itepekimab (Anti-IL-33)	Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD.
A2434	Daclizumab (Anti-IL-2Ra / CD25)	Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD.
A2435	Basiliximab (Anti-IL-2Ra / CD25)	Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD.
E2502	Tamarixetin	Tamarixetin (4'-O-Methyl Quercetin) is a natural flavonoid derivative of quercetin and has superior anti-inflammatory properties in bacterial sepsis by increasing the population of IL-10-secreting immune cells.
A2437	Tildrakizumab (Anti-IL-23a)	Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD.
A2438	Guselkumab (Anti-IL-23)	Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD.
A2439	Anti-IL-22Ra	Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD.
S0777	Isuzinaxib (APX-115 free base)	Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
A2440	Fezakinumab (Anti-IL-22)	Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD.
A2883	Gevokizumab (Anti-IL-1b)	Gevokizumab (Anti-IL-1b) is an IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. MW: 145.12 KD.
A2441	Fletikumab (Anti-IL-20)	Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD.
E0008	Atractylodin	Atractylodin (Atractydin) is one of the major constituents of the rhizome of Atractylodes lancea and inhibits N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity with an IC50 of 2.81 µM. Atractylodin also inhibits interleukin-6 (IL-6) by blocking NPM-ALK activation and MAPKs.
A2442	Spesolimab (Anti-IL-1RL2 / IL-36R)	Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD.
A2443	Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R)	Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD	Microbiol Spectr, 2024, 12(8):e0061224
S0781	IQ 3	IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro.	Int J Biol Sci, 2024, 20(6):2323-2338
A2444	Nidanilimab (Anti-IL-1RAP / IL-1R3)	Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD.	Nat Commun, 2025, 16(1):2493 bioRxiv, 2024, 2024.04.24.590852
A2446	Canakinumab (Anti-IL-1b)	Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD.	Cell Mol Life Sci, 2025, 82(1):216
A2447	Bermekimab (Anti-IL-1a)	Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD.
A2448	Anti-IL-18	Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD.	Cancer Sci, 2024, 10.1111/cas.16287
A2451	Ordesekimab (Anti-IL-15)	Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD.
A2453	Tralokinumab (Anti-IL-13)	Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD.
A2454	Abrezekimab (Anti-IL-13)	Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD.
A2038	Dupilumab (anti-IL-4Rα)	Dupilumab (anti-IL-4Rα) is a fully human anti–interleukin-4 receptor α monoclonal antibody that inhibits both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling through blockade of the shared IL-4α subunit.	Sci Adv, 2024, 10(26):eadn5229
S6579	RCGD423	RCGD-423 is a modulator of Glycoprotein 130 (gp130, IL6ST, IL6-beta, CD130) signalling that regulates cartilage growth and differentiation.
S5973	Methylprednisolone Acetate	Methylprednisolone (NSC-19987, Medrol) acetate is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis.
A2118	Anti-mouse IL-6-InVivo	Anti-mouse IL-6-InVivo monoclonal antibody (Clone:MP5-20F3) can reacts with mouse IL-6 (interleukin-6) which is a 21-28 kDa cytokine that is expressed by many cell types, including T lymphocytes, B lymphocytes, monocytes, fibroblasts, and endothelial cells. Anti-mouse IL-6-InVivo has been shown to neutralize the bioactivity of natural or recombinant IL-6.	Nat Commun, 2025, 16(1):289 Research (Wash D C), 2024, 7:0538 J Biol Chem, 2024, S0021-9258(24)01877-5
S4966	4-Methylesculetin	4-methylesculetin is one of the coumarin derivatives with great anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase (MPO) activity and reduces IL-6 level.
A2916	Anti-GD2 (EMD 273063)	Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD.
P1235^New	Raleukin	Anakinra (Raleukin, AMG-719) is an exogenous antagonist of recombinant human interleukin-1 receptor that also inhibits caspase-1 and caspase-9 activity with Ki of 0.201 μM and 0.31 μM respectively. It is used in research to study IL-1 blockade in inflammation, tumor growth, islet transplantation, and cardiac injury models.	Inflammation, 2025, 10.1007/s10753-025-02315-3
S9054	Pectolinarin	Pectolinarin is a major compound in Cirsium setidens with anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin induces apoptosis via inactivation of the PI3K/Akt pathway.
E1153	LMT-28	LMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130.
S3293	Gardenoside	Gardenoside is a natural compound extracted from Gardenia fruits, with hepatoprotective properties. Gardenoside inhibits TNF-α, IL-1β, IL-6 and NFκB activation. Gardenoside also has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside suppresses the pain in rats model of chronic constriction injury by regulating the P2X3 and P2X7 receptors.
A2946	Anti-IL-10 (BT-063)	Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD.
S3292	(3R,8S)-Falcarindiol	Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.	Antioxidants (Basel), 2024, 13(12)1533 Front Cell Infect Microbiol, 2023, 13:1128000 Front Pharmacol, 2021, 12:656697
A2947	Briakinumab (Anti-IL-12) (IL-12a & IL-12b)	Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.
A2949	Cendakimab (Anti-IL-13)	Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD.
S9660	Remibrutinib	Remibrutinib is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.
A2950	Dectrekumab (Anti-IL-13)	Dectrekumab (anti-IL-13) is a humanized monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD.
S0139	MD2-TLR4-IN-1	MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively.
A2951	Anti-IL-13 (GSK 679586)	Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD.
A2952	Anti-IL-13 (H2L6)	Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD.
A2953	Anti-IL-13 (IMA-026)	Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD.
A2954	Lebrikizumab (Anti-IL-13)	Lebrikizumab (anti-IL-13) is an humanized IgG4 monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD.
A2955	Anti-IL-13 (M1295)	Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD.
A2958	Anti-IL-15 (DISC0280)	Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD.
A2959	Anti-IL-18 (ABT-325)	Anti-IL-18 (ABT-325) is a humanized monoclonal antibody targeted against interleukin-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD.
A2960	Anti-IL-1b (CDP484)	Anti-IL-1b (CDP484) is an antibody targated against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD.
A2962	Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R)	Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD.
S3871	Muscone	Muscone (3-Methylcyclopentadecanone, Methylexaltone), a flavouring ingredient, is an organic compound that is the primary contributor to the odor of musk and also a potent anti-inflammatory agent. Muscone significantly downregulats the levels of LPS-induced inflammatory cytokines and inhibits NF-κB and NLRP3 inflammasome activation in BMDMs. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6).	Ecotoxicol Environ Saf, 2025, 292:117961 J Pharm Pharmacol, 2019, 71(11):1706-1713
A2964	Avizakimab (Anti-IL-21)	Avizakimab (Anti-IL-21) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets interleukin-21. MW: 145.42 KD.
S9075	Mulberroside A	Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
A2965	Brazikumab (Anti-IL-23)	Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD.
A2966	Anti-IL-23 (LY2525623)	Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD.
A2967	Mirikizumab (Anti-IL-23)	Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD.
A2968	Camidanlumab (Anti-IL-2Ra / CD25)	Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of hematological tumors. MW: 143.98 KD.
A2972	Anti-IL-4Ra / CD124 (MEDI2045)	Anti-IL-4Ra / CD124 (MEDI2045) is a high-affinity human and Cynomolgus cross-reactive antibody that blocks the functional interaction of IL-4 and IL-13 with their obligate receptor, IL-4Ra. MEDI 2045 has the potential to treat severe, uncontrolled asthma. MW: 143.76 KD.
A2973	Anti-IL-5 (Abgenix anti-IL-5)	Anti-IL-5 (Abgenix anti-IL-5) is a human monoclonal antibody against interleukin-5. MW: 145.0 KD.
A2163	Anti-mouse IL-12 p40-InVivo	Anti-mouse IL-12 p40-InVivo reacts with mouse p40 also known as IL-12β. p40 is a 40 kDa subunit of IL-12 and IL-23. IL-12 is a heterodimeric cytokine composed of subunits IL-12α p35 and IL-12β p40.
A2975	Anti-IL-6 / IFNb2 (Chugai SK2)	Anti-IL-6 / IFNb2 (Chugai SK2) is a humanized mouse monoclonal antibody that specifically binds to IL-6 and strongly inhibits IL-6 functions. MW: 145.46 KD.
A2978	Anti-IL-6 / IFNb2 (MEDI 5117)	Anti-IL-6/IFNb2 (MEDI 5117) is a human monoclonal antibody against Interleukin-6 (IL-6), a pleiotropic cytokine with immune regulation, inflammation, and oncogenesis. It has the potential to treat rheumatoid arthritis (RA). MW: 145.14 KD.
A2980	Sirukumab (Anti-IL-6 / IFNb2)	Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD.
A2981	Ziltivekimab (Anti-IL-6 / IFNb2)	Ziltivekimab (Anti-IL-6 / IFNb2) is a human monoclonal antibody targeting IL-6. It has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD. MW :145.14 KD.
A2982	Anti-IL-6Ra / CD126 (APX007)	Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD.
S6850	NE 52-QQ57	NE 52-QQ57 is a selective, and orally available antagonist of G-protein coupled receptor 4 (GPR4) with IC50 of 0.07 μM. NE 52-QQ57 effectively blocks GPR4-mediated cAMP accumulation with IC50 of 26.8 nM in HEK293 cells. The antagonism of GPR4 with NE 52-QQ57 significantly inhibits the AGE-induced increased expression of several key inflammatory cytokines and signaling molecules, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2).	Exp Hematol Oncol, 2024, 13(1):13
A2983	Levilimab (Anti-IL-6Ra / CD126)	Levilimab (Anti-IL-6Ra / CD126) is a fully human monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an inflammation-alleviating antibody and can be used for the research of rheumatoid arthritis and covid-19 treatment. MW :145.62 KD.
A2984	Sapelizumab (Anti-IL-6Ra / CD126)	Sapelizumab (Anti-IL-6Ra / CD126) is a human monoclonal antibody targeting IL-6. It is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. MW :144.26 KD.
A2985	Olokizumab (Anti-IL-6 / IFNb2)	Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD.
S9417	Homoplantaginin	Homoplantaginin (Hispidulin-7-glucoside), a main flavonoid from a traditional Chinese medicine Salvia plebeia, has anti-inflammatory and anti-oxidant properties. Homoplantaginin inhibits TNF-α and IL-6 mRNA expression, IKKβ and NF-κB phosphorylation.	Front Pharmacol, 2025, 16:1526107
A4001^New	Tibulizumab (Anti-BAFF & IL-17)	Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
S5579	Chelidonic acid	Chelidonic acid (Jerva acid, Jervaic acid, γ-Pyrone-2,6-dicarboxylic acid) is a secondary metabolite found in several plants with therapeutic potential in allergic disorders in experimental animals. Chelidonic acid inhibits IL-6 production by blocking NF-κB and caspase-1 in HMC-1 cells. Chelidonic acid is also an inhibitor of glutamate decarboxylase with Ki of 1.2 μM.
A4004^New	Lutikizumab (Anti-IL-1α & IL-1β)	Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.
A4006^New	Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin)	Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.
E2630	SKF-86002	SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
E1383	Cp2-SO4	Cp2-SO4 is a phenylalanine derivative which reverses interleukin 4 induced 1 (IL4I1)-dependet inhibition of T-cell proliferation with Ki of 21.2 µM.	Cancers (Basel), 2024, 16(9)1622
A4017^New	Mas825 (Anti-IL-18 & IL-1β)	Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: 144.15 kDa.
A4018^New	Romilkimab (Anti-IL-13 & IL-4)	Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.
S6347	5'-N-Ethylcarboxamidoadenosine (NECA)	5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
A4020^New	Abt-122 (Anti-IL-17 & TNF-alpha)	Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.
S9129	20(S)-Ginsenoside Rh1	20(S)-Ginsenoside Rh1 (Prosapogenin A2, Sanchinoside B2, Sanchinoside Rh1) is one of major bioactive compounds extracted from red ginseng, which has been increasingly used for enhancing cognition and physical health worldwide. It exhibits potent characteristics of anti-inflammatory, antioxidant, immunomodulatory effects, and positive effects on the nervous system. Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
A2138	Anti-mouse IL-2-InVivo	Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation
S3138	Methylthiouracil	Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
E0177	Hydrocortisone sodium succinate	Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. Hydrocortisone sodium succinate can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators.
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
A4043^New	Cova322 (Anti-IL-17 & TNF-Alpha)	Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.
S3261	Myrislignan	Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan inhibits interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). Myrislignan significantly inhibits the expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Myrislignan inhibits the NF-κB signalling pathway activation.	Oxid Med Cell Longev, 2023, 2023:7098313
S0228	SU 5201	SU 5201 (NSC 247030) is an interleukin-2 (IL-2) inhibitor.
S3304	Stylopine	Stylopine ((R,S)-Stylopine, Tetrahydrocoptisine) reduces nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), and the IL-6 production and cyclooxygenase-2 (COX-2) activity caused by the LPS stimulation. Stylopine is a major component of the leaf of Chelidonium majus L.
A2797	Anti-IL-25	Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD.
A2801	Anti-IL-13 (CNTO 607)	Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.
S9184	Forsythoside B	Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant. Forsythoside B has potent neuroprotective effects and has anti-inflammation, antioxidant, and antisepsis properties. Forsythoside B could inhibit TNF-alpha, IL-6, IκB and modulate NF-κB.
A2030	Siltuximab (anti-IL-6)	Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6).
S3299	Demethyleneberberine	Demethyleneberberine (DMB), a component of Cortex Phellodendri Chinensis (CPC), significantly alleviates the weight loss and diminishes myeloperoxidase (MPO) activity, while significantly reduces the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), and inhibits the activation of NF-κB signaling pathway. Demethyleneberberine (DMB) potentially ameliorates NAFLD (Non-alcoholic fatty liver disease) by activating AMPK pathways.
A2032	Brodalumab (anti-IL17RA)	Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R).
S7455	Resatorvid (TAK-242)	Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy.	Carbohydr Polym, 2025, 350:122980 J Neuroinflammation, 2025, 22(1):38 Phytomedicine, 2025, 142:156645
S1189	Aprepitant	Aprepitant is a potent and selective neurokinin-1 receptor antagonist with IC50 of 0.1 nM. Aprepitant reduces levels of pro-inflammatory cytokines including G-CSF, IL-6, IL-8 and TNFα. Aprepitant inhibits HIV infection of human macrophages.	Br J Cancer, 2024, 10.1038/s41416-024-02608-8 Inflammation, 2023, 46(1):256-269 Nat Commun, 2022, 13(1):4995
S8966	T-5224	T-5224 is a selective inhibitor of transcription factor c-Fos/activator protein (AP)-1 with anti-inflammatory effects. T-5224 specifically inhibits the DNA binding activity of c-Fos/c-Jun and the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.	MedComm (2020), 2025, 6(4):e70154 iScience, 2025, 28(4):112176 J Immunol Res, 2025, 2025:4821639
S6414	Apilimod	Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.	J Cell Biol, 2025, 224(6)e202408158 Cells, 2024, 13(11)953 bioRxiv, 2024, 2024.02.28.582543
S7259	FLLL32	FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.	Cancer Commun -Lond), 2023, 43(10):1117-1142 Microbiol Res, 2023, 276:127480 Research Square, 2023, Version 1
S8301	Ossirene (AS101)	Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme.	Mol Neurodegener, 2025, 20(1):5 Cell Biosci, 2025, 15(1):18 Stem Cell Rev Rep, 2025, none
S4267	Diacerein	Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.	MedComm (2020), 2024, 5(8):e668 Oral Dis, 2022, 10.1111/odi.14294 Free Radic Biol Med, 2021, 165:171-183
S1733	Methylprednisolone	Methylprednisolone is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis.	Food Chem Toxicol, 2024, 188:114665 Drug Test Anal, 2020, 10.1002/dta.2917 Nat Med, 2017, 23(4):424-428
S9727	Ac-YVAD-cmk	Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective IL-1β converting enzyme (ICE) inhibitor with neuroprotective and anti-inflammatory effects, effectively suppresses the expression of IL-1β and IL-18.	Cell Commun Signal, 2024, 22(1):368 J Transl Med, 2024, 22(1):1139 Int J Mol Sci, 2024, 25(4)2185
S8261	GSK583	GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. GSK583 also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures.	J Invest Dermatol, 2025, S0022-202X(25)00494-4 Cancer Res, 2020, canres.530.2020 J Neuroinflammation, 2020, 17(1):364
S0785	Apilimod mesylate	Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.	bioRxiv, 2024, 2024.02.28.582543 Stem Cell Reports, 2022, 17(2):397-412 Hum Mol Genet, 2021, 29(22):3589-3605
S0787	3-Deazaadenosine hydrochloride	3-Deazaadenosine HCl (3-DZA, c3Ado) is a potent inhibitor of S-adenosylhomocysteine hydrolase with Ki of 3.9 µM. 3-Deazaadenosine HCl inhibits bacterial lipopolysaccharide-induced transcription of TNF-α and IL-1β. 3-Deazaadenosine HCl inhibits the transcriptional activity of NF-κB, prevents FCS-induced Ras carboxyl methylation and reduces FCS-induced ERK1/2 and Akt phosphorylation. 3-Deazaadenosine HCl has anti-inflammatory, anti-proliferative and anti-HIV activities.	J Exp Clin Cancer Res, 2022, 41(1):36 Free Radic Biol Med, 2021, 168:25-43
S9668	PKR-IN-C16	PKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.	Exp Mol Med, 2024, 56(2):408-421. EMBO J, 2024, 43(5):780-805. Respir Res, 2024, 25(1):201
S8879	Deucravacitinib (BMS-986165)	Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.	Res Sq, 2025, rs.3.rs-6079043 Nat Commun, 2024, 15(1):1718 Nat Commun, 2024, 15(1):1337
S0826	A-740003	A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. A-740003 potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells.	Am J Cancer Res, 2024, 14(2):585-600 Cell Rep, 2023, 42(7):112696
S6898	RCM-1	RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin.	Parasit Vectors, 2025, 18(1):100 J Mol Histol, 2024, 55(6):1259-1270 Front Immunol, 2022, 13:863034
S5972	Hydrocortisone hemisuccinate	Hydrocortisone hemisuccinate (A-hydrocort, Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid with anti-inflammatory properties, is an inhibitor of proinflammatory cytokine with IC50 of 6.7 μM and 21.4 μM for Interleukin-6 (IL-6) and IL-3, respectively.	J Transl Med, 2023, 21(1):50
S9052	Auraptene	Auraptene (7-geranyloxycoumarin) is a natural coumarin derived from citrus plants and possesses valuable pharmacological properties, including anticarcinogenic, anti-inflammatory, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene inhibits matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8 and chemokine (C-C motif) ligand-5(CCL5).	Neuropharmacology, 2025, 269:110352 Plant Physiology, 2012, 81–94
S9374	2',5'-Dihydroxyacetophenone	2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.	Pathol Oncol Res, 2019, 25(1):301-309
S6620	Danirixin (GSK1325756)	Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 (IL-8) binding = 12.5 nM), selective, and reversible CXCR2 antagonist.	Redox Biol, 2024, 76:103323 Theranostics, 2019, 9(18):5332-5346
S0437	SAR-20347	SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling.	Cancer Discov, 2023, 13(2):410-431 Cancer Discov, 2023, 13(2):410-431
S9502	Madecassic acid	Madecassic acid (Brahmic acid), a natural triterpene first isolated from C. asiatica, has diverse anti-inflammatory and anti-diabetic effects, blocking NF-κB activation in macrophages and causing by iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 inhibition.	Drug Des Devel Ther, 2022, 16:3793-3804
S0472	EC330	EC330 is a steroidal inhibitor of leukemia inhibitory factor (LIF, an interleukin 6 class cytokine). EC330 inhibits the LIF/LIF-R signaling and blocks the promoting effects of LIF on growth and migration of cancer cells.	NPJ Precis Oncol, 2024, 8(1):246 Br J Cancer, 2021, 10.1038/s41416-021-01631-3
S1833	Butoconazole nitrate	Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively).
S3312	Diethyl phosphate	Diethyl phosphate (DEP, DPF, Diethyl phosphoric acid, diethyl hydrogen phosphate), a non-specific metabolite of organophosphorus pesticides in the gut environment, significantly enriches opportunistic pathogens leading to a decrease in interleukin-6 (IL-6).
S5764	YM 90709	YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).
S3590	Triolein	Triolein is an inhibitor of metalloproteinase-1 (MMP-1) and reduces both the expression of IL-6 and ROS generation in irradiated keratinocytes.
E3067	Trionycis Carapax Extract	Trionycis Carapax Extract is obtained from Carapax Trionycis, of which Carapax Trionycis extracts with molecular weight less than 6 KD (CT6) down-regulates TNF-α, IL-1β and IL-6 expression in TGF-β1-treated HSC-T6, indicating the potential therapeutic effect of these extracts against liver fibrosis.
E0314	JTE-607 Dihydrochloride	JTE-607 Dihydrochloride is a prodrug compound that is converted to an active form by ester hydrolysis. JTE-607 is a multiple cytokine production inhibitor that targets CPSF3 and inhibits pre-mRNA processing. JTE-607 inhibits tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50 values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively.
S3969	Veratric acid	Veratric acid (3,4-Dimethoxybenzoic acid), a simple benzoic acid derived from plants and fruits, has anti-oxidant, anti-inflammation, and blood pressure-lowering effects. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation.
S9236	α-Cyperone	α-Cyperone (alpha-cyperone), a major active compound of Cyperus rotundus, exhibits biological activities, such as antivirulence, antigenotoxic, and antibacterial activities. α-Cyperone (alpha-cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1.
S0752	AUDA	AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. AUDA has anti-inflammatory activity that reduces the protein expression of MMP-9, IL-1β, TNF-α and TGF-β. AUDA downregulates Smad3 and p38 signaling pathways.
S0777	Isuzinaxib (APX-115 free base)	Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
E0008	Atractylodin	Atractylodin (Atractydin) is one of the major constituents of the rhizome of Atractylodes lancea and inhibits N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity with an IC50 of 2.81 µM. Atractylodin also inhibits interleukin-6 (IL-6) by blocking NPM-ALK activation and MAPKs.
S0781	IQ 3	IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro.	Int J Biol Sci, 2024, 20(6):2323-2338
S5973	Methylprednisolone Acetate	Methylprednisolone (NSC-19987, Medrol) acetate is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis.
S4966	4-Methylesculetin	4-methylesculetin is one of the coumarin derivatives with great anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase (MPO) activity and reduces IL-6 level.
S9054	Pectolinarin	Pectolinarin is a major compound in Cirsium setidens with anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin induces apoptosis via inactivation of the PI3K/Akt pathway.
E1153	LMT-28	LMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130.
S3293	Gardenoside	Gardenoside is a natural compound extracted from Gardenia fruits, with hepatoprotective properties. Gardenoside inhibits TNF-α, IL-1β, IL-6 and NFκB activation. Gardenoside also has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside suppresses the pain in rats model of chronic constriction injury by regulating the P2X3 and P2X7 receptors.
S3292	(3R,8S)-Falcarindiol	Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.	Antioxidants (Basel), 2024, 13(12)1533 Front Cell Infect Microbiol, 2023, 13:1128000 Front Pharmacol, 2021, 12:656697
S9660	Remibrutinib	Remibrutinib is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.
S0139	MD2-TLR4-IN-1	MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively.
S3871	Muscone	Muscone (3-Methylcyclopentadecanone, Methylexaltone), a flavouring ingredient, is an organic compound that is the primary contributor to the odor of musk and also a potent anti-inflammatory agent. Muscone significantly downregulats the levels of LPS-induced inflammatory cytokines and inhibits NF-κB and NLRP3 inflammasome activation in BMDMs. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6).	Ecotoxicol Environ Saf, 2025, 292:117961 J Pharm Pharmacol, 2019, 71(11):1706-1713
S9075	Mulberroside A	Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
S6850	NE 52-QQ57	NE 52-QQ57 is a selective, and orally available antagonist of G-protein coupled receptor 4 (GPR4) with IC50 of 0.07 μM. NE 52-QQ57 effectively blocks GPR4-mediated cAMP accumulation with IC50 of 26.8 nM in HEK293 cells. The antagonism of GPR4 with NE 52-QQ57 significantly inhibits the AGE-induced increased expression of several key inflammatory cytokines and signaling molecules, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2).	Exp Hematol Oncol, 2024, 13(1):13
S9417	Homoplantaginin	Homoplantaginin (Hispidulin-7-glucoside), a main flavonoid from a traditional Chinese medicine Salvia plebeia, has anti-inflammatory and anti-oxidant properties. Homoplantaginin inhibits TNF-α and IL-6 mRNA expression, IKKβ and NF-κB phosphorylation.	Front Pharmacol, 2025, 16:1526107
S5579	Chelidonic acid	Chelidonic acid (Jerva acid, Jervaic acid, γ-Pyrone-2,6-dicarboxylic acid) is a secondary metabolite found in several plants with therapeutic potential in allergic disorders in experimental animals. Chelidonic acid inhibits IL-6 production by blocking NF-κB and caspase-1 in HMC-1 cells. Chelidonic acid is also an inhibitor of glutamate decarboxylase with Ki of 1.2 μM.
E2630	SKF-86002	SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
E1383	Cp2-SO4	Cp2-SO4 is a phenylalanine derivative which reverses interleukin 4 induced 1 (IL4I1)-dependet inhibition of T-cell proliferation with Ki of 21.2 µM.	Cancers (Basel), 2024, 16(9)1622
S6347	5'-N-Ethylcarboxamidoadenosine (NECA)	5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
S9129	20(S)-Ginsenoside Rh1	20(S)-Ginsenoside Rh1 (Prosapogenin A2, Sanchinoside B2, Sanchinoside Rh1) is one of major bioactive compounds extracted from red ginseng, which has been increasingly used for enhancing cognition and physical health worldwide. It exhibits potent characteristics of anti-inflammatory, antioxidant, immunomodulatory effects, and positive effects on the nervous system. Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
S3138	Methylthiouracil	Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
E0177	Hydrocortisone sodium succinate	Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. Hydrocortisone sodium succinate can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators.
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
S3261	Myrislignan	Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan inhibits interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). Myrislignan significantly inhibits the expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Myrislignan inhibits the NF-κB signalling pathway activation.	Oxid Med Cell Longev, 2023, 2023:7098313
S0228	SU 5201	SU 5201 (NSC 247030) is an interleukin-2 (IL-2) inhibitor.
S3304	Stylopine	Stylopine ((R,S)-Stylopine, Tetrahydrocoptisine) reduces nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), and the IL-6 production and cyclooxygenase-2 (COX-2) activity caused by the LPS stimulation. Stylopine is a major component of the leaf of Chelidonium majus L.
S9184	Forsythoside B	Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant. Forsythoside B has potent neuroprotective effects and has anti-inflammation, antioxidant, and antisepsis properties. Forsythoside B could inhibit TNF-alpha, IL-6, IκB and modulate NF-κB.
S3299	Demethyleneberberine	Demethyleneberberine (DMB), a component of Cortex Phellodendri Chinensis (CPC), significantly alleviates the weight loss and diminishes myeloperoxidase (MPO) activity, while significantly reduces the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), and inhibits the activation of NF-κB signaling pathway. Demethyleneberberine (DMB) potentially ameliorates NAFLD (Non-alcoholic fatty liver disease) by activating AMPK pathways.
A2025	Secukinumab (anti-IL-17A)	Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.	American Scientific Publishers, 2024, 174-182(9) Signal Transduct Target Ther, 2022, 7(1):80 Biochem Pharmacol, 2021, 192:114728
A2120	Anti-mouse IL-17A-InVivo	Anti-mouse IL-17A-InVivo monoclonal antibody (Clone:17F3) reacts with mouse IL-17A which is a 15-20 kDa cytokine expressed by Th17 cells, γδ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. Anti-mouse IL-17A-InVivo has been shown to neutralize IL-17A in vivo.	Autoimmunity, 2025, 58(1):2515825 World J Gastrointest Oncol, 2025, 17(1):97831 Int Immunopharmacol, 2024,
A2375	Rolinsatamab (Anti-PRLR / Prolactin Receptor)	Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD.
A2822	Depemokimab (Anti-IL-5)	Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD.
A2142	Anti-mouse/rat IL-1β-InVivo	Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes.	Signal Transduct Target Ther, 2025, 10(1):161
A2842	Ebdarokimab (Anti-IL-12b)	Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW : 145.6 KD.
A2153	Anti-mouse IL-2 (S4B6-1)-InVivo	Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation.
A2845	Elsilimomab (Anti-IL-6 / IFNb2)	Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD.
A2157	Anti-mouse IL-6R-InVivo	Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily.
A2046	Risankizumab (anti-IL-23)	Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.
A2856	Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)	Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD.
A2861	Anti-CTLA-8 / IL-17a (CAT-2200)	Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72.
A2862	Ixekizumab (Anti-CTLA-8 / IL-17a)	Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD.
A2863	Netakimab (Anti-CTLA-8 / IL-17a)	Netakimab (Anti-CTLA-8 / IL-17a) is a humanized monoclonal antibody against interleukin-17 (IL-17) with the potential to treat moderate to severe plaque psoriasis. MW: 145.74 KD.
A2024	Ustekinumab (anti-IL-12/IL-23)	Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.
A2864	Perakizumab (Anti-CTLA-8 / IL-17a)	Perakizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG1κ monoclonal antibody against interleukin-17A (IL-17A). MW: 145.8 KD.
A2134	Anti-mouse IL-18-InVivo	Anti-mouse IL-18-InVivo (Clone:YIGIF74-1G7) monoclonal antibody reacts with mouse IL-18. IL-18 an 18 kDa pro-inflammatory cytokine is expressed by activated macrophages, keratinocytes, Kupffer cells, intestinal epithelial cells, and osteoblasts.
A2609	Clazakizumab (Anti-IL-6 / IFNb2)	Clazakizumab (Anti-IL-6 / IFNb2) is a monoclonal antibody targeting the IL-6 (interleukin-6). It inhibitsg the cytokine response to SARS-CoV-2 in COVID-19 and can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. MW :145.24 KD.
A2423	Enokizumab (Anti-IL-9)	Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD.
A2610	Vobarilizumab (Anti-IL-6Ra / CD126)	Vobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD.
A2866	Vunakizumab (Anti-CTLA-8 / IL-17a)	Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.
A2428	Mepolizumab (Anti-IL-5)	Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD.
A2430	Pascolizumab (Anti-IL-4)	Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD.
A2432	Itepekimab (Anti-IL-33)	Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD.
A2434	Daclizumab (Anti-IL-2Ra / CD25)	Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD.
A2435	Basiliximab (Anti-IL-2Ra / CD25)	Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD.
A2437	Tildrakizumab (Anti-IL-23a)	Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD.
A2438	Guselkumab (Anti-IL-23)	Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD.
A2439	Anti-IL-22Ra	Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD.
A2440	Fezakinumab (Anti-IL-22)	Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD.
A2883	Gevokizumab (Anti-IL-1b)	Gevokizumab (Anti-IL-1b) is an IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. MW: 145.12 KD.
A2441	Fletikumab (Anti-IL-20)	Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD.
A2442	Spesolimab (Anti-IL-1RL2 / IL-36R)	Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD.
A2443	Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R)	Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD	Microbiol Spectr, 2024, 12(8):e0061224
A2444	Nidanilimab (Anti-IL-1RAP / IL-1R3)	Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD.	Nat Commun, 2025, 16(1):2493 bioRxiv, 2024, 2024.04.24.590852
A2446	Canakinumab (Anti-IL-1b)	Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD.	Cell Mol Life Sci, 2025, 82(1):216
A2447	Bermekimab (Anti-IL-1a)	Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD.
A2448	Anti-IL-18	Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD.	Cancer Sci, 2024, 10.1111/cas.16287
A2451	Ordesekimab (Anti-IL-15)	Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD.
A2453	Tralokinumab (Anti-IL-13)	Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD.
A2454	Abrezekimab (Anti-IL-13)	Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD.
A2038	Dupilumab (anti-IL-4Rα)	Dupilumab (anti-IL-4Rα) is a fully human anti–interleukin-4 receptor α monoclonal antibody that inhibits both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling through blockade of the shared IL-4α subunit.	Sci Adv, 2024, 10(26):eadn5229
A2118	Anti-mouse IL-6-InVivo	Anti-mouse IL-6-InVivo monoclonal antibody (Clone:MP5-20F3) can reacts with mouse IL-6 (interleukin-6) which is a 21-28 kDa cytokine that is expressed by many cell types, including T lymphocytes, B lymphocytes, monocytes, fibroblasts, and endothelial cells. Anti-mouse IL-6-InVivo has been shown to neutralize the bioactivity of natural or recombinant IL-6.	Nat Commun, 2025, 16(1):289 Research (Wash D C), 2024, 7:0538 J Biol Chem, 2024, S0021-9258(24)01877-5
A2916	Anti-GD2 (EMD 273063)	Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD.
A2946	Anti-IL-10 (BT-063)	Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD.
A2947	Briakinumab (Anti-IL-12) (IL-12a & IL-12b)	Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.
A2949	Cendakimab (Anti-IL-13)	Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD.
A2950	Dectrekumab (Anti-IL-13)	Dectrekumab (anti-IL-13) is a humanized monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD.
A2951	Anti-IL-13 (GSK 679586)	Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD.
A2952	Anti-IL-13 (H2L6)	Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD.
A2953	Anti-IL-13 (IMA-026)	Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD.
A2954	Lebrikizumab (Anti-IL-13)	Lebrikizumab (anti-IL-13) is an humanized IgG4 monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD.
A2955	Anti-IL-13 (M1295)	Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD.
A2958	Anti-IL-15 (DISC0280)	Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD.
A2959	Anti-IL-18 (ABT-325)	Anti-IL-18 (ABT-325) is a humanized monoclonal antibody targeted against interleukin-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD.
A2960	Anti-IL-1b (CDP484)	Anti-IL-1b (CDP484) is an antibody targated against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD.
A2962	Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R)	Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD.
A2964	Avizakimab (Anti-IL-21)	Avizakimab (Anti-IL-21) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets interleukin-21. MW: 145.42 KD.
A2965	Brazikumab (Anti-IL-23)	Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD.
A2966	Anti-IL-23 (LY2525623)	Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD.
A2967	Mirikizumab (Anti-IL-23)	Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD.
A2968	Camidanlumab (Anti-IL-2Ra / CD25)	Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of hematological tumors. MW: 143.98 KD.
A2972	Anti-IL-4Ra / CD124 (MEDI2045)	Anti-IL-4Ra / CD124 (MEDI2045) is a high-affinity human and Cynomolgus cross-reactive antibody that blocks the functional interaction of IL-4 and IL-13 with their obligate receptor, IL-4Ra. MEDI 2045 has the potential to treat severe, uncontrolled asthma. MW: 143.76 KD.
A2973	Anti-IL-5 (Abgenix anti-IL-5)	Anti-IL-5 (Abgenix anti-IL-5) is a human monoclonal antibody against interleukin-5. MW: 145.0 KD.
A2163	Anti-mouse IL-12 p40-InVivo	Anti-mouse IL-12 p40-InVivo reacts with mouse p40 also known as IL-12β. p40 is a 40 kDa subunit of IL-12 and IL-23. IL-12 is a heterodimeric cytokine composed of subunits IL-12α p35 and IL-12β p40.
A2975	Anti-IL-6 / IFNb2 (Chugai SK2)	Anti-IL-6 / IFNb2 (Chugai SK2) is a humanized mouse monoclonal antibody that specifically binds to IL-6 and strongly inhibits IL-6 functions. MW: 145.46 KD.
A2978	Anti-IL-6 / IFNb2 (MEDI 5117)	Anti-IL-6/IFNb2 (MEDI 5117) is a human monoclonal antibody against Interleukin-6 (IL-6), a pleiotropic cytokine with immune regulation, inflammation, and oncogenesis. It has the potential to treat rheumatoid arthritis (RA). MW: 145.14 KD.
A2980	Sirukumab (Anti-IL-6 / IFNb2)	Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD.
A2981	Ziltivekimab (Anti-IL-6 / IFNb2)	Ziltivekimab (Anti-IL-6 / IFNb2) is a human monoclonal antibody targeting IL-6. It has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD. MW :145.14 KD.
A2982	Anti-IL-6Ra / CD126 (APX007)	Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD.
A2983	Levilimab (Anti-IL-6Ra / CD126)	Levilimab (Anti-IL-6Ra / CD126) is a fully human monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an inflammation-alleviating antibody and can be used for the research of rheumatoid arthritis and covid-19 treatment. MW :145.62 KD.
A2984	Sapelizumab (Anti-IL-6Ra / CD126)	Sapelizumab (Anti-IL-6Ra / CD126) is a human monoclonal antibody targeting IL-6. It is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. MW :144.26 KD.
A2985	Olokizumab (Anti-IL-6 / IFNb2)	Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD.
A4001^New	Tibulizumab (Anti-BAFF & IL-17)	Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
A4004^New	Lutikizumab (Anti-IL-1α & IL-1β)	Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.
A4006^New	Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin)	Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.
A4017^New	Mas825 (Anti-IL-18 & IL-1β)	Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: 144.15 kDa.
A4018^New	Romilkimab (Anti-IL-13 & IL-4)	Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.
A4020^New	Abt-122 (Anti-IL-17 & TNF-alpha)	Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.
A2138	Anti-mouse IL-2-InVivo	Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation
A4043^New	Cova322 (Anti-IL-17 & TNF-Alpha)	Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.
A2797	Anti-IL-25	Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD.
A2801	Anti-IL-13 (CNTO 607)	Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.
A2030	Siltuximab (anti-IL-6)	Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6).
A2032	Brodalumab (anti-IL17RA)	Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R).
S1709	Estradiol	Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.	Nat Commun, 2025, 16(1):758 Cells, 2025, 14(10)703 iScience, 2024, 27(3):109125
S2979	CU-T12-9	CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.	Nat Commun, 2025, 16(1):2743 Biomedicine & Pharmacotherapy, 2023, 114638 Biomed Pharmacother, 2023, 162:114638
S0771	BRD6989	BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA).	Infect Drug Resist, 2021, 14:3135-3143
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
E2502	Tamarixetin	Tamarixetin (4'-O-Methyl Quercetin) is a natural flavonoid derivative of quercetin and has superior anti-inflammatory properties in bacterial sepsis by increasing the population of IL-10-secreting immune cells.
S2015	Suplatast Tosylate	Suplatast Tosylate (IPD-1151T, Suplatast Tosilate) is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.	J Transl Med, 2022, 20(1):615
P1252^New	JNJ-77242113(Icotrokinra)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
P1235^New	Raleukin	Anakinra (Raleukin, AMG-719) is an exogenous antagonist of recombinant human interleukin-1 receptor that also inhibits caspase-1 and caspase-9 activity with Ki of 0.201 μM and 0.31 μM respectively. It is used in research to study IL-1 blockade in inflammation, tumor growth, islet transplantation, and cardiac injury models.	Inflammation, 2025, 10.1007/s10753-025-02315-3
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Int J Nanomedicine, 2024, 19:3589-3605 Front Immunol, 2024, 15:1331480 J Inflamm Res, 2024, 17:9757-9771
S6281	Sodium Thiocyanate	Sodium Thiocyanate (NaSCN, Sodium rhodanide, Sodium sulfocyanate, Sodium rhodanate), one of the main sources of the thiocyanate anion, is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals. Sodium thiocyanate (NaSCN) reduces IL-6, whereas increases IL-10 levels. Sodium thiocyanate also reduces ROS.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S3745	Balsalazide disodium	Balsalazide Disodium is the disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide Disodium suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.	Front Microbiol, 2020, 10:2936
S4842	Balsalazide	Balsalazide (Colazal, Giazo), an aminosalicylate and oral prodrug, is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
S6579	RCGD423	RCGD-423 is a modulator of Glycoprotein 130 (gp130, IL6ST, IL6-beta, CD130) signalling that regulates cartilage growth and differentiation.
F2146^New	IL-18 Rabbit mAb	IL18,IL-18
P1252^New	JNJ-77242113(Icotrokinra)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
P1235^New	Raleukin	Anakinra (Raleukin, AMG-719) is an exogenous antagonist of recombinant human interleukin-1 receptor that also inhibits caspase-1 and caspase-9 activity with Ki of 0.201 μM and 0.31 μM respectively. It is used in research to study IL-1 blockade in inflammation, tumor growth, islet transplantation, and cardiac injury models.	Inflammation, 2025, 10.1007/s10753-025-02315-3
A4001^New	Tibulizumab (Anti-BAFF & IL-17)	Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
A4004^New	Lutikizumab (Anti-IL-1α & IL-1β)	Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.
A4006^New	Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin)	Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.
A4017^New	Mas825 (Anti-IL-18 & IL-1β)	Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: 144.15 kDa.
A4018^New	Romilkimab (Anti-IL-13 & IL-4)	Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.
A4020^New	Abt-122 (Anti-IL-17 & TNF-alpha)	Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.
A4043^New	Cova322 (Anti-IL-17 & TNF-Alpha)	Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.

Choose Selective Interleukins Inhibitors